NCT02531425View on ClinicalTrials.gov

Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions
BIOLOGICAL

IT-pIL12-EP

Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions

Trial Locations (1)

94305-5826

Stanford University, Stanford

All Listed Sponsors
lead

OncoSec Medical Incorporated

INDUSTRY

NCT02531425 - Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC | Biotech Hunter | Biotech Hunter